10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
PR Newswire•07/10/2026•09:00 ET
0
Key Highlights
- ➤10x Genomics (TXG) and Fred Hutch announce multi-project cancer research collaboration
- ➤First clinical research initiative extends 10x’s oncology work into blood cancers
- ➤Bladder cancer project uses Flex Apex and Xenium to study treatment-response biomarkers
- ➤AML project investigates Flex Apex for residual disease detection after treatment
- ➤Collaboration includes framework for future clinical reporting and treatment planning
Expert Statements
Lawrence Fong, Scientific director of Fred Hutch's Integrated Immunotherapy Research Center
“This project will help us better characterize the cellular and molecular responses to cancer treatments. We look forward to seeing how the results of this research could help guide treatment decisions for people with cancer.”
Serge Saxonov, Co-founder and CEO of 10x Genomics
“Across cancer care, we have more effective therapies than ever, and too little insight into which patient will actually benefit from which one.”
Serge Saxonov, Co-founder and CEO of 10x Genomics
“Single cell and spatial biology let us look directly at the biology that drives treatment response, whether it's in a tumor or in the blood, and we believe that's the missing foundation for precision oncology. We're excited to work with Fred Hutch on this research.”
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers PR Newswire
Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia
Get started
Create a free account to read the full story.